3,017 Gilead Sciences, Inc. $GILD Shares Bought by CacheTech Inc.

CacheTech Inc. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 24.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,228 shares of the biopharmaceutical company’s stock after acquiring an additional 3,017 shares during the quarter. CacheTech Inc.’s holdings in Gilead Sciences were worth $2,270,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of GILD. BlackRock Inc. bought a new stake in Gilead Sciences in the 2nd quarter valued at about $15,393,785,000. State Street Corp increased its holdings in shares of Gilead Sciences by 2.3% during the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Amundi raised its position in shares of Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after buying an additional 1,018,976 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $1,316,606,000. Finally, Boston Partners raised its position in shares of Gilead Sciences by 8.4% in the third quarter. Boston Partners now owns 6,523,864 shares of the biopharmaceutical company’s stock valued at $970,367,000 after buying an additional 505,906 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $166.33 on Friday. The stock has a 50-day moving average price of $157.26 and a two-hundred day moving average price of $142.46. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $176.58. The company has a market capitalization of $206.30 billion, a PE ratio of -52.64 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same quarter in the previous year, the business earned $2.47 earnings per share. Gilead Sciences’s revenue was up 6.8% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $171.47, for a total transaction of $514,410.00. Following the completion of the sale, the chief financial officer owned 158,096 shares in the company, valued at approximately $27,108,721.12. The trade was a 1.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the completion of the sale, the insider owned 110,684 shares in the company, valued at $18,877,156.20. This represents a 20.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 237,709 shares of company stock valued at $39,799,137. 0.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Citigroup boosted their price target on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research note on Friday, October 30th. BMO Capital Markets restated an “outperform” rating and set a $184.00 price objective on shares of Gilead Sciences in a research note on Friday, October 30th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, October 30th. TD Cowen set a $175.00 target price on Gilead Sciences in a research report on Wednesday. Finally, Cantor Fitzgerald increased their target price on Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $171.63.

Check Out Our Latest Analysis on Gilead Sciences

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.